he iShares Nasdaq Biotechnology ETF (IBB) was outperforming the broader market all year. Emphasis on past tense, because as of Tuesday, that’s no longer true.

A steep October selloff triggered by mediocre earnings reports has persisted into November. The IBB is market-cap weighted, so notable laggards Celgene (CELG), Alexion Pharma (ALXN), Regeneron Pharma (REGN) and Incyte (INCY) exert an oversized drag on performance. The IBB is now returning just a touch under 15 percent for the year. That’s still good, albeit slightly underperforming the SPDR S&P 500 ETF (SPY), which tracks the S&P 500.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Olivia Harper Cancel reply

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.